Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cost Control”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources
PubMed1977

A simple cost control format in clinical laboratories.

Laboratory scientists must be able to demonstrate their proficiency not just in the analysis of specimens but also financial management. The cost information in real dollar term is the only way to measure the productivity of a laboratory. We have demonstrated a simple procedure in tabulating the income and expenditure of our laboratories. In our hand, we have found the information to be useful and timely for various decisions and plannings.

Chemistry, Clinical↗
PubMed2006

The self-control costs of fighting the temptation to drink.

Being exposed to the sight and smell of an alcoholic beverage and not drinking it should require self-control. On the basis of the self-control strength model (M. Muraven & R. F. Baumeister, 2000), exerting self-control should lead to poorer performance on subsequent self-control tasks. Using a cue exposure paradigm, the authors had 160 social drinkers alternately sniff water and alcohol. After each trial, the drinkers engaged in 2 self-control tasks: squeezing a handgrip and a self-stopping task. Performance on these tasks was worse after sniffing alcohol than after sniffing water. Mood and arousal did not mediate the effects; urge to drink was negatively related to outcomes. The effects were stronger for individuals high in trait temptation to drink. Resisting the temptation of drinking appears to undermine self-control capacity.

Adult↗
PubMed1990

Navy shoves off for cost-control waters.

The U.S. Navy is the latest branch of the armed services to launch managed care as part of its CHAMPUS strategy against a barrage of healthcare cost increases.

Health Benefit Plans, Employee↗
PubMed1986

Health insurance trends in cost control and coverage.

An analysis of changes in company health plans between 1979 and 1984 shows that employers often sought to contain rising expenditures, in some cases, increasing the cost to workers; improvements in benefits, however, continued.

Data Collection↗
PubMed1979

Multilevel care. A Veterans Administration initiative in health care cost control.

The Veterans Administration's (VA) Department of Medicine and Surgery, the largest of the civilian federal health care systems, is under continuous White House, congressional, and public pressure to provide greater accountability and increased cost-effectiveness for its $5 billion-plus annual budget. Responding to these pressures, the VA is evaluating in ten of its 172 medical centers a new system of resource allocation and financial management known as a multilevel care system. This is a major VA intiative with highly important implications for both the VA and the private health care sector.

Cost-Benefit Analysis↗
PubMed1984

Health Maintenance Organizations and state DRG hospital cost control programs: the need for federal preemption.

The growth of Health Maintenance Organizations (HMOs) as alternatives to the conventional health care system is the result of HMOs' financial competitiveness and their ability to provide efficient health care without wasteful and costly medical procedures. An HMO's goal is to minimize the cost of providing responsible medical care. As a result, HMOs attempt to limit the length of stay of a patient in a hospital by providing alternatives to hospital care. They achieve a competitive advantage by utilizing less expensive methods of treatment. The emergence of diagnostically related group (DRG) regulatory systems threaten the viability of HMOs by eliminating their competitive advantage. State-adopted DRG systems require hospitals to charge a fixed rate to all patients with similar diagnoses. This eliminates the advantage an HMO might gain by reducing a patient's length of stay. The Author argues that since HMOs are federally supported, they should be exempt from any DRG system implemented by a state. Further, the Author argues that while federal law ostensibly eliminates the conflict between HMOs and the DRG systems, HMOs are still restrained from free negotiations with hospitals. Accordingly, the Author contends that courts should apply federal statutes that encourage HMOs, preempt state laws, and thus allow HMOs to negotiate freely with hospitals regarding the rates of payment for patients.

Costs and Cost Analysis↗
PubMed1995

Designs for age of cost control. This year's Design Awards Competition winners find that aesthetics can help the bottom line.

Should healthcare architecture emphasize aesthetics or solutions to problems? This question sums up the discussion of judges for Modern Healthcare's 10th annual Design Awards Competition. Judging by the award winners, cost pressures and increasing competition in the healthcare industry seem to be making both design aesthetics and functionality more important.

Architecture↗
PubMed1994

[Quality assurance and cost control in invasive and interventional cardiology].

We report our experience of Quality Assurance in a Cardiac Catheterization Laboratory of the National Health Service. An attempt was made to apply these criteria to the medical activities as well as to the management and economic aspects of our work. Limits and perspectives of this experience are discussed as a contribution to ongoing debate among cardiologists and public health Authorities.

Costs and Cost Analysis↗
PubMed1990

Biopharmaceutical payment and coverage: are cost control policies too restrictive? Industrial Biotechnology Association.

The use of recombinant DNA technology and monoclonal antibody technology has led to a variety of new "biopharmaceuticals" that aid the body in fighting disease. We are already seeing improvements in patients' quality of life as a result of these new technologies. Often, we also see a lowering of health care costs due to preventing or shortening hospital stays and the reduction of the need for other health care expenditures. However, it is important to recognize that there is also the possibility of an increase in health care costs as the new drugs enable people to live longer, and thus possibly consume more health care services. In recent years, a rising concern has been voiced about the rapid increase in health care spending. Despite vital health and economic benefits made possible by new pharmaceuticals, spending on drugs is a relatively small portion of total health care expenditures. As consumers demand access to high-quality health care, the issue of reimbursement has become highly controversial. As we stated earlier, we recognize that HCFA and other third-party payers have a legitimate interest in attempting to control health care expenditures. However, we are aware that restrictive policies on drug coverage and payment could deprive patients of access to medically necessary therapies and, ultimately, reduce biopharmaceutical manufacturers' revenues to the point where future research is hampered or halted.

Biotechnology↗
PubMed1992

The new nurse manager: a linchpin in quality care and cost control.

An important shift is taking place in the nursing area, where the old "head nurse" position is giving way to a new phenomenon--the nurse manager, an individual whose responsibility and authority are broader and more strategic. The nurse manager is becoming a key player in hospitals' efforts to satisfy patient needs, hold down costs and maximize efficiency; indeed, this "linchpin" manager is being given authority over budgeting, capital equipment expenditures, employee evaluations and patient care outcomes. But are the nurses now in hospitals up to the challenge? And are hospital executives prepared to make the human resources investment necessary to ensure the success of the new nurse managers?

Career Mobility↗